MoneyWorks4Me

Hind Bio Science - Quaterly Results

31 Oct 2023 Evaluate
Revenue showed a marginal decline at Rs. 3.17 millions. For the quarter ended September 2023, as compared to corresponding quarter of last year.The Total Profit for the quarter ended September 2023 of Rs. 0.66 millions grew from Rs.-0.75 millions Operating profit Margin for the quarter ended September 2023 improved to 0.68% as compared to -0.73% of corresponding quarter ended September 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 3.17 0.00 0.00 3.17 2.71 16.97 9.22 4.31 113.92
Other Income 0.10 0.00 0.00 0.10 0.00 0.00 0.00 0.00 0.00
PBIDT 0.68 -0.73 -193.15 -0.52 -0.97 -46.39 -0.28 -5.06 -94.47
Interest 0.01 0.01 0.00 0.02 0.01 100.00 0.04 0.05 -20.00
PBDT 0.67 -0.74 -190.54 -0.54 -0.98 -44.90 -0.32 -5.11 -93.74
Depreciation 0.01 0.01 0.00 0.02 0.02 0.00 0.06 0.03 100.00
PBT 0.66 -0.75 -188.00 -0.56 -1.00 -44.00 -0.38 -5.14 -92.61
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.03 -33.33
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.03 -33.33
PAT 0.66 -0.75 -188.00 -0.56 -1.00 -44.00 -0.40 -5.17 -92.26
Equity 20.50 102.51 -80.00 20.50 102.51 -80.00 20.50 102.51 -80.00
PBIDTM(%) 21.45 0.00 0.00 -16.40 -35.79 -54.17 -3.04 -117.40 -97.41
Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..